Taurodeoxycholic acid sodium hydrate (Sodium taurodeoxycholate monohydrate) 是一种胆汁酸，是由肝脏中的胆固醇合成的两亲性表面活性剂分子。 除TGR5通路外，Taurodeoxycholic acid sodium hydrate 还激活S1PR2通路。
| 生物活性 | Taurodeoxycholic acid sodium hydrate (Sodium taurodeoxycholate monohydrate), a bile acid, is an amphiphilic surfactant molecule synthesized fromcholesterolin the liver. Taurodeoxycholic acid sodium hydrate activates theS1PR2pathway in addition to theTGR5pathway[1]. |
| IC50& Target[1] | |
体外研究
(In Vitro) | The median plasma concentration of Taurodeoxycholate is 33.9 nM in healthy individuals[1].
Taurodeoxycholate inhibits the binding of N-3H-methylscopolamine to the M3 muscarinic receptor of acetylcholine with an IC50of 170 μM[1].
Taurodeoxycholate (0.05-1.00 mM; 1-6 days) stimulates intestinal epithelial cell proliferation[2].
Taurodeoxycholate (0.05-1.00 mM; 24 h) induces a significant increase in S-phase concentration and a significant decrease in G1-phase concentration of the cell cycle, increases c-myc protein and mRNA expression in IEC-6 cells[2].
Cell Proliferation Assay[2] | Cell Line: | IEC-6 and caco-2 cells | | Concentration: | 0, 0.05, 0.50, and 1.00 mM | | Incubation Time: | 1, 2, 4 and 6 days | | Result: | Significantly stimulated intestinal epithelial cell proliferation in a dose-dependent manner. |
Cell Cycle Analysis[2] | Cell Line: | IEC-6 cells | | Concentration: | 0, 0.05, 0.50, and 1.00 mM | | Incubation Time: | 24 h | | Result: | Significantly increased cells in S phase and decreased cells in G1-phase. |
Western Blot Analysis[2] | Cell Line: | IEC-6 cells | | Concentration: | 0.5 mM | | Incubation Time: | 1 and 6 days | | Result: | Significantly increased c-myc protein expression. |
|
体内研究
(In Vivo) | Taurodeoxycholate (0.5 mg/kg; i.v.; once) confers protection to C57BL/6N mice with sepsis, but does not protect TGR5 KO mice under sepsis[1].
| Animal Model: | C57BL/6N mice,Lipopolysaccharides(HY-D1056) injection model of sepsis[1] | | Dosage: | 0.5 mg/kg | | Administration: | Intravenous injection, 30 min or 24 h after LPS injection | | Result: | Improved the survival rate of mice with sepsis. Decreased liver and kidney damage in septic mice. Ameliorated systemic inflammation and normalized blood pressure in septic mice. |
|
| 分子量 | |
| 性状 | |
| Formula | |
| CAS 号 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
| 溶解性数据 | In Vitro: DMSO : 125 mg/mL(231.61 mM;Need ultrasonic) 配制储备液 | 1 mM | 1.8529 mL | 9.2644 mL | 18.5288 mL | | 5 mM | 0.3706 mL | 1.8529 mL | 3.7058 mL | | 10 mM | 0.1853 mL | 0.9264 mL | 1.8529 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture)。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂： ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂： 0.5%CMC-Na/saline water Solubility: 20 mg/mL (37.06 mM); Clear solution; Need ultrasonic 2. 请依序添加每种溶剂： 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.08 mg/mL (3.85 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (3.85 mM，饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。 3. 请依序添加每种溶剂： 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.08 mg/mL (3.85 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (3.85 mM，饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。 4. 请依序添加每种溶剂： 10% DMSO 90%corn oil Solubility: ≥ 2.08 mg/mL (3.85 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (3.85 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。 *以上所有助溶剂都可在本网站选购。
|
m.cnreagent.com